UCB bets $2B on Candid's T cell engager ambitions

May 3, 2026 09:54 PM EDT DealsChina UCB bets $2 bil­lion on Can­did's T cell en­gager am­bi­tions Kyle LaHucik Biotech Correspondent Ken Song has done it again. The bio­phar­ma vet­er­an’s all-out ef­fort to prove T cell en­gagers’ po­ten­tial in au­toim­mune dis­eases is get­ting picked up by … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER